{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-24-030773","form_type":"8-K","ticker":"NVCT","cik":"0001875558","company_name":"Nuvectis Pharma, Inc.","filed_at":"2024-03-05T23:59:59+00:00","discovered_at":"2026-05-14T18:03:26.193612+00:00","generated_at":"2026-06-05T04:13:02.470239+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"confidence":"high","headline":"Nuvectis Pharma FY2023 net loss $22.3M; cash $19.1M; NXP800 data update expected March 2024","bullets":["Cash and cash equivalents $19.1M at Dec 31, 2023, down from $20.0M at Dec 31, 2022.","Net loss for FY2023 was $22.3M vs $19.1M in FY2022; includes $4.7M non-cash stock compensation.","R&D expenses increased to $15.4M from $13.2M; G&A increased to $7.5M from $6.0M.","NXP800 Phase 1b preliminary data update expected in March 2024 for platinum-resistant ARID1a-mutated ovarian cancer.","NXP900 Phase 1a dose escalation initiated; multiple clinical data readouts expected in 2024."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-24-030773","json":"https://secwatch.observer/filing/0001104659-24-030773.json","markdown":"https://secwatch.observer/filing/0001104659-24-030773.md","text":"https://secwatch.observer/filing/0001104659-24-030773.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1875558/000110465924030773/0001104659-24-030773-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1875558/000110465924030773/tm247868d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-05T04:13:02.470239+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"67a2cf60ccec4aa7c7ad45b4c400d9aac7523312","claim":"Nuvectis Pharma, Inc. reported the fiscal year ended December 31, 2023 results: net income $22.3 million.","evidence_excerpt":"The Company's net loss was $22.3 million for the year ended December 31, 2023, compared to $19.1 million for the year ended December 31, 2022","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1875558/000110465924030773/0001104659-24-030773-index.htm","confidence":1.0,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the fiscal year ended December 31, 2023"},{"label":"Net income","value":"$22.3 million"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}